Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-2506PO in Alzheimer's Disease
NCT00083421Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jun 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing ONO-2506PO with Placebo (2 arms). Primary endpoints: Cognitive Function Scale and Global Function Scale. Started Jun 2004; status: completed.
02
Drugs
arundic acid
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00083421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083421.